



Epigenomics

Approaching the Chinese market

Epigenomics' partner BioChain reported positive results from a Chinese clinical study of its blood-based colorectal cancer test Epi proColon, indicating 74.8% sensitivity, non-inferior to the 68% for an approved faecal-based test. There is opportunity to gain early ground in China as incidence and awareness grows; the company estimates c 290 million people are eligible for testing. Meanwhile, the pending FDA approval decision is the key catalyst for the further recovery in the share price.

CFDA clinical study data for Epi proColon

Epigenomics' partner BioChain reported data from its Chinese clinical study of the Epi proColon test from 1,074 patients in three centres. The data showed sensitivity of 74.8% (true positives) and specificity of 97.4% (true negatives) within the cohort, which included 300 colorectal cancer (CRC) sufferers. The Chinese approval application was submitted ahead of target, so the test could be on the market in 2015. Epigenomics is eligible for upfront and milestone payments plus royalties for Chinese approval and launch through BioChain.

China a growing market

The incidence of colorectal cancer in China is rising and predicted to grow rapidly due to changes in diet and lifestyle, and the ageing population. Approved screening methods include colonoscopy and stool-based testing, but there is no centralised CRC screening policy in China. However, with the incidence rate growing at up to 5% per year, testing is becoming more widely available. Epi proColon could gain market share, particularly as it is a low cost, minimally invasive method.

FDA approval decision for Epi proColon is key driver

Following submission of the FDA approval filing, Epigenomics remains confident that the data submitted support the approval application. A post-approval longitudinal study is being designed to demonstrate the long-term accuracy of Epi proColon. The US holds the key market potential given the government target to increase compliance from 60% to 80% and likely support for a blood-based rather than a stool-based test.

Valuation: US approval decision is key catalyst


There is potential upside from the current EV of c €79m based on possible approval by the FDA. China is a high growth market providing additional commercial potential for Epi proColon.

Consensus estimates						
Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/12	1.0	(12.0)	(1.3)	0.0	N/A	N/A
12/13	1.6	(7.3)	(0.6)	0.0	N/A	N/A
12/14e	4.2	(9.2)	(0.6)	0.0	N/A	N/A
12/15e	13.1	(8.4)	(0.5)	0.0	N/A	N/A
Source: Blo	ombera					

Pharma & biotech

6 May 2014





Share details Code ECX Listing Frankfurt Shares in issue 13.5m

Business description

Epigenomics is a German molecular diagnostics company focused on the early detection of cancer. Its main product is Epi proColon, a blood-based DNA test for colorectal cancer, which uses a sophisticated PCR assay to detect methylated copies of the Septin9 gene.

Bull

- Size of Chinese population and with growing awareness and incidence of CRC.
- Opportunity to enter at an early stage of market growth in China.
- Growth in reimbursement for medical therapies in China creates demand for screening methods.

Bear

- Lack of government CRC screening policy in China.
- Chinese market would not support high-priced testing.
- Uncertainty of the FDA decision.

Analysts

Emma Ulker +44 (0)20 3077 5738 Dr Mick Cooper +44 (0)20 3077 5734

healthcare@edisongroup.com



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firm/BasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. NZ is registered on the New Zealand Financial Services only. Edison Investment Research Investment Research Investment Research Limited (Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus.) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Epigenomics and prepared and issued by Edison for publication globally. All information used in the publication of this report compiled from publicy available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research and to be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US reliable to the publishers only. Edison US registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" for investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subscribe, or underwine any securities. The presearch in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document